HUNTINGTON BEACH, Calif.--(BUSINESS WIRE)--Cicero Diagnostics, Inc., the provider of the ReceptivaDx™ test, today announced its scientific advisor, Bruce Lessey, will be featured at the virtual Endometriosis Summit being held October 24-25th to speak on BCL6 and its role in infertility. His topic is Strategies for improving outcomes through early detection of endometriosis in the infertility clinic.
Dr. Lessey will be featured on Sunday, Oct. 25th at 3pm. The event will be accessible here.
Dr. Lessey, a practicing reproductive endocrinologist and expert in endometrial dysfunction, observed a connection between the presence of the protein BCL6 and undiagnosed endometriosis that allowed the development of a breakthrough test for endometriosis called ReceptivaDx. Over the last four years, ReceptivaDx has provided fertility centers the diagnostic and treatment pathway necessary to detect and treat endometriosis in women whose only symptom may be unexplained infertility.
“Specialists are taking another look at endometriosis as a cause of otherwise unexplained infertility,” said Chris Jackson, CEO of Cicero Diagnostics. “The breadth of published research as well as the experience of our clients over the last two years continues to reinforce that diagnosis and treatment of endometriosis produces increased success rates on subsequent IVF transfers. There is a significant percentage of women who experience infertility but never see a specialist or explore their options - our hope is that the on-going research Cicero Diagnostics is doing to expand treatment pathways and other biomarkers will increase patient access to treatment,” concluded Mr. Jackson.
About Cicero Diagnostics
Cicero Diagnostics is a medical diagnostic company located in Huntington Beach, California. ReceptivaDx is the company’s signature test panel in the area of unexplained infertility. Cicero Diagnostics is the exclusive licensed provider of the BCL6 test for the detection of uterine lining dysfunction commonly associated with endometriosis. Cicero Diagnostics continues to expand their offering globally and is investing in continued research in the field. They are currently involved in a large multicenter NIH grant with Stanford, University of North Carolina and Wake Forest universities. ReceptivaDx is being used at more than 300 infertility centers across the US and 15 countries worldwide.